Hamm-Alvarez SF
Department of Pharmaceutical Sciences, USC School of Pharmacy, 1985 Zonal Avenue, Los Angeles, CA-90033, USA.
Pharm Sci Technol Today. 1999 May;2(5):190-196. doi: 10.1016/s1461-5347(99)00143-1.
Gene therapy provides a major new therapeutic strategy for the treatment of disease. Despite its potential for the inhibition of disease progression at the molecular level, gene therapy has faced numerous challenges. Foremost amongst these is the introduction of a sufficient amount of DNA-based drug to the target cell under conditions that encourage persistence of the introduced DNA. Because many DNA-based drugs enter cells via receptor-mediated endocytosis, clearly modulation of this process is a key issue in maximizing DNA persistence. In this review, a particular protein that participates in receptor-mediated endocytosis, the microtubule-based motor protein, cytoplasmic dynein, is introduced. In addition, recent advances in the study of cytoplasmic dynein in receptor-mediated endocytosis are discussed, and there is consideration of the potential of cytoplasmic dynein as a critical target for the regulation of DNA-uptake and persistence.
基因治疗为疾病治疗提供了一种全新的主要治疗策略。尽管它在分子水平上具有抑制疾病进展的潜力,但基因治疗面临着诸多挑战。其中最主要的挑战是在促使导入的DNA持续存在的条件下,将足够量的基于DNA的药物导入靶细胞。由于许多基于DNA的药物通过受体介导的内吞作用进入细胞,显然调节这一过程是使DNA持续存在最大化的关键问题。在这篇综述中,介绍了一种参与受体介导内吞作用的特定蛋白质,即基于微管的动力蛋白——细胞质动力蛋白。此外,还讨论了细胞质动力蛋白在受体介导内吞作用研究中的最新进展,并探讨了将细胞质动力蛋白作为调节DNA摄取和持续存在的关键靶点的潜力。